| New IPA-Biomarker™ Capability
Critical for Expression Diagnostics Discovery and Development
Redwood City, CA – July 10, 2007
– Ingenuity Systems, the leading provider of solutions
to explore, analyze, and interpret scientific literature
and data, today announced that XDx, a leading molecular
diagnostics company, has licensed Ingenuity’s flagship
solution IPA 5.0. Ingenuity Systems was selected by XDx
after a comprehensive evaluation of several pathway analysis
products.
Founded in 2000, XDx is a molecular diagnostics company
based in Brisbane, California. Setting the stage for a
new era in personalized medicine, XDx is one of the first
companies to develop and commercialize practical applications
built on insights from the Human Genome Project. The company
has developed a proprietary new method for noninvasively
monitoring the immune system by measuring gene expression
in a patient’s peripheral blood. The technology
offers the potential to decrease healthcare costs and
significantly improve the quality of life for patients
with a variety of life-threatening or life-altering immune-mediated
diseases.
"We chose IPA because it best meets our objective
to identify and understand biomarkers associated with
immune-mediated diseases,” commented Dr. Tod Klingler,
VP of Informatics at XDx. “IPA provides us with
access to its extensive knowledge base of gene function
information assembled from the scientific literature through
easy-to-use tools that our researchers can use to rapidly
evaluate candidate biomarkers. Specifically, IPA allows
us to make sense of our gene expression data in the context
of known immune system interactions and pathways.”
"We are very pleased to have been selected by XDx
as an important tool in their research programs,”
stated Peter DiLaura, Senior Vice President, Commercial
Operations at Ingenuity Systems. “As with many of
our customers involved in biomarker research, IPA is well-suited
for XDx because the expansive, expert-extracted scientific
content can be applied in their initial exploratory research,
and then tools in IPA, such as IPA-Biomarker™, can
be used to identify or compare their biomarker candidates.
IPA 5.0 enables them to apply filters to their data to
determine whether a particular gene or protein is detectable
in sentinel tissues or other bodily fluids, so potential
candidates are identified much more effectively than in
traditional approaches.”
Ingenuity Pathways Analysis is a software application
that enables researchers to model, analyze, and understand
the complex biological and chemical systems at the core
of life science research. IPA is deployed in all major
pharmaceutical companies and in hundreds of biotechnology
companies and academic institutions globally. It supports
analysis of data from all experimental platforms, and
is used at all stages of the drug discovery and development
process, including target identification and validation,
identification of biomarkers, predictive toxicology, and
pharmacogenomics.
Trials of Ingenuity Pathways Analysis 5.0 are currently
being offered at http://www.ingenuity.com/trial.
For more information about Ingenuity Pathways Analysis,
please email sales@ingenuity.com
or go to www.ingenuity.com
About Ingenuity Systems®
Ingenuity enables researchers to model, analyze, and understand
complex biological and chemical systems foundational to
human health and disease. The Ingenuity products include
pathways analysis software and knowledge bases for life
scientists and bioinformaticians, and enterprise knowledge
management infrastructure, content and services for leading
pharmaceutical and biotech companies. Ingenuity was founded
in 1998 and is headquartered in Redwood City, California
with offices in Germany, Switzerland, France, the United
Kingdom, and Japan. www.ingenuity.com.
About XDx
XDx’s mission is to improve patient care by developing
molecular diagnostics that translate an individual’s
immune status into clinically actionable information. XDx
is a molecular diagnostics company that utilizes state-of-the-art
genomic technology and sophisticated bioinformatics analyses
to understand and measure the immune processes that underlie
specific immune-mediated conditions. Physicians can use
this information to optimize patient treatment and minimize
the long-term consequences of immunosuppressive therapies.
XDx’s science and technology is now being evaluated
in patients with solid organ transplants. Building on
the discoveries made during the development of AlloMap®
testing for heart transplant patients, which included
the identification of many genes and pathways involved
in tissue rejection, XDx is now developing a product for
use by physicians to better manage lung transplant patients.
Beyond the use of AlloMap testing in assessing immune
response in solid organ transplantation, XDx scientists
are applying similar approaches to create new molecular
diagnostic tests for the improved clinical management
of immune-mediated inflammatory diseases, such as systemic
lupus erythematosus (SLE or lupus,) to diagnose and predict
clinical flares common in a variety of these diseases.
Contact:
Heidi Bullock
Director, Marketing
Ingenuity Systems
650.381.5150
Tammy Reilly
Vice President, Commercial Operations
XDx
650.287.2300
>
View as PDF 
|
